Published in Int J Tuberc Lung Dis on February 01, 2010
Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur Respir J (2012) 2.99
Spatial patterns of pulmonary tuberculosis incidence and their relationship to socio-economic status in Vitoria, Brazil. Int J Tuberc Lung Dis (2010) 1.24
A pragmatic approach to measuring, monitoring and evaluating interventions for improved tuberculosis case detection. Int Health (2014) 0.98
Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet (2015) 0.94
"Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis. BMC Health Serv Res (2014) 0.92
Household contact investigation for tuberculosis in Vietnam: study protocol for a cluster randomized controlled trial. Trials (2013) 0.81
Migration to middle-income countries and tuberculosis-global policies for global economies. Global Health (2017) 0.75
Screening strategies for active tuberculosis: focus on cost-effectiveness. Clinicoecon Outcomes Res (2016) 0.75
The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med (1994) 16.32
Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med (1994) 13.11
Tuberculosis in New York City--turning the tide. N Engl J Med (1995) 6.69
The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med (1994) 4.87
Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet (2006) 4.58
Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis (2008) 4.14
Control strategies for tuberculosis epidemics: new models for old problems. Science (1996) 3.59
Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol (2003) 3.09
Eleven years of community-based directly observed therapy for tuberculosis. JAMA (1995) 2.27
Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet (2000) 2.26
The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis (2001) 2.23
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis (1999) 2.18
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA (2007) 2.13
Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis (1999) 1.82
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med (2006) 1.55
Modeling the epidemiology and economics of directly observed therapy in Baltimore. Int J Tuberc Lung Dis (2000) 1.52
Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2001) 1.45
The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tuber Lung Dis (1994) 1.39
The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ (2009) 1.35
Transmission of Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. Am J Respir Crit Care Med (2001) 1.06
The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis (1998) 1.02
Tuberculosis incidence among contacts of active pulmonary tuberculosis. Int J Tuberc Lung Dis (2009) 0.86
Improvements in treatment success rates with directly observed therapy in Rio de Janeiro City. Int J Tuberc Lung Dis (2006) 0.81
Tuberculin skin testing among BCG-vaccinated children who are household contacts. Int J Tuberc Lung Dis (2001) 0.78
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
A physical map of the human genome. Nature (2001) 12.39
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med (1993) 8.49
Chlamydial infection. Isolation of Chlamydia from patients with non-specific genital infection. Br J Vener Dis (1972) 7.92
E-cadherin germline mutations in familial gastric cancer. Nature (1998) 6.72
Mechanisms of lactose utilization by lactic acid streptococci: enzymatic and genetic analyses. J Bacteriol (1970) 6.34
Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 5.80
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature (1992) 5.47
The antigenic structure of proteins: a reappraisal. Annu Rev Immunol (1984) 5.31
Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health (1987) 5.06
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis (2005) 4.36
Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23
Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. J Clin Microbiol (1995) 4.11
Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis (1987) 4.11
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol (1994) 4.07
Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med (1994) 4.04
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr (2001) 3.67
Age differences in the frontal lateralization of verbal and spatial working memory revealed by PET. J Cogn Neurosci (2000) 3.66
Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.64
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Chlamydial infections of the cervix. Br J Vener Dis (1974) 3.48
Routine prenatal screening for HIV infection. Lancet (1991) 3.43
IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol (1998) 3.37
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet (1998) 3.37
Duodenal mucosal damage in 31 infants with gastroenteritis. Arch Dis Child (1973) 3.35
Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke (1997) 3.26
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy. JAMA (1998) 3.07
Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med (1983) 3.00
Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med (1990) 2.97
Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis (2006) 2.97
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology (1995) 2.90
Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis (1983) 2.83
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med (1991) 2.77
Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS (1999) 2.73
Surgical complication outcome (SCOUT) score: a new method to evaluate quality of care in vascular surgery. J Vasc Surg (1997) 2.67
Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses (2004) 2.64
The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev (1987) 2.56
Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother (1999) 2.54
Spontaneous mutations in the CsrRS two-component regulatory system of Streptococcus pyogenes result in enhanced virulence in a murine model of skin and soft tissue infection. J Infect Dis (2001) 2.51
Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med (1991) 2.46
Errors in the treatment of tuberculosis in Baltimore. Chest (2000) 2.46
Effect of tumor necrosis factor alpha on mitogen-activated human B cells. J Exp Med (1987) 2.42
Projections of AIDS morbidity and mortality in San Francisco. JAMA (1990) 2.42
Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis (2005) 2.40
Rotavirus infection and rates of hospitalisation for acute gastroenteritis in young children in Australia, 1993-1996. Med J Aust (1998) 2.39
Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem (2000) 2.37
Cell wall and protoplast isoperoxidases in relation to injury, indoleacetic Acid, and ethylene effects. Plant Physiol (1974) 2.36
Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res (2003) 2.35
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology (2012) 2.34
Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.29
Quasi-hexagonal molecular packing in collagen fibrils. Nature (1980) 2.28
Eleven years of community-based directly observed therapy for tuberculosis. JAMA (1995) 2.27
Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol (1984) 2.25
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy. JAMA (2000) 2.25
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med (1987) 2.21
Intestinal biopsy in childhood. Arch Dis Child (1973) 2.21
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis (1999) 2.18
Latent tuberculosis infection among undergraduate medical students in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis (2005) 2.16
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. Am J Med (2001) 2.15
Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med (1996) 2.14
Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med (1991) 2.12
Improved survival of patients with cystic fibrosis. Med J Aust (1979) 2.12
Fine specificity of regulatory T cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in a genetically nonresponder mouse strain. J Exp Med (1979) 2.12
Phonons and the elastic moduli of collagen and muscle. Nature (1977) 2.09
Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. JAMA (1991) 2.08
Incidence of salmonellosis in patients with AIDS. J Infect Dis (1987) 2.04
Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev (2006) 2.04
Mycobacteria and AIDS mortality. Am Rev Respir Dis (1989) 2.02
Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis (1995) 2.01
Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. J Consult Clin Psychol (2001) 1.99
The present status of the heterogeneity of fetal hemoglobin in beta-thalassemia: an attempt to unify some observations in thalassemia and related conditions. Ann N Y Acad Sci (1974) 1.99
Determination of the elastic constants of collagen by Brillouin light scattering. J Mol Biol (1979) 1.97
Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis (1998) 1.97
The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis (2013) 1.96
Changes in pulmonary function in workers exposed to vinyl chloride and polyvinyl chloride. Ann N Y Acad Sci (1975) 1.95
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol (1996) 1.92
Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Mol Psychiatry (2005) 1.91
Different functional specificity repertoires for suppressor and helper T cells. Immunol Rev (1978) 1.91
Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis (2006) 1.91
Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.89
Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS (2001) 1.88
Mean and instantaneous expiratory flows, FVC and FEV1: prediction equations from a probability sample of Michigan, a large industrial state. Bull Eur Physiopathol Respir (1987) 1.88
Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med (1994) 1.87
Paradoxical worsening of tuberculosis in HIV-infected persons. Chest (2001) 1.78
Monocular elevation weakness and ptosis: an oculomotor fascicular syndrome? J Clin Neuroophthalmol (1991) 1.78
Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis (2011) 1.76
Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care (2007) 1.75
Audit of emergency preoperative resuscitation. Br J Surg (1994) 1.73
Volatile compounds produced in sterile fish muscle (Sebastes melanops) by Pseudomonas perolens. Appl Microbiol (1973) 1.73
Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol (1997) 1.72
Epidemiology of rotavirus serotypes in Melbourne, Australia, from 1973 to 1989. J Clin Microbiol (1991) 1.72
Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. Int J Tuberc Lung Dis (2011) 1.71
Structure of insect fibrillar flight muscle in the presence and absence of ATP. J Mol Biol (1972) 1.70